Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company's macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell t... Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company's macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. The Company's lead product candidate, CT-0508, is a Chimeric Antigen Receptor Macrophage (CAR-M) to be evaluated in a human clinical trial and is intended to treat solid tumors that overexpress HER2. The Company's second product candidate, CT-0525, is also intended to treat solid tumors that overexpress HER2, is in preclinical development. Beyond CT-0508 and CT-0525, the Company has a pipeline of cell therapy assets in various stages of pre-clinical development. The Company is also developing in vivo CAR-M gene therapies. Mehr anzeigen
Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024 PR Newswire PHILADELPHIA, Nov. 17, 2024...
Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma PR Newswire PHILADELPHIA, Nov. 8, 2024 New findings showcase the potential of in vivo...
Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights PR Newswire PHILADELPHIA, Nov. 7, 2024 Initial results from the Phase 1 study of CT-0525, lead...
Regulatory News : CARMILA (Paris:CARM) : Date Nombre d’actions composant le capital social Nombre réel de droits de vote (déduction faite des actions auto-détenues) Nombre théorique de droits de...
Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024 PR Newswire PHILADELPHIA, Nov. 5, 2024 Pre-clinical data demonstrate robust...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.08 | -8.51063829787 | 0.94 | 0.94 | 0.8224 | 143204 | 0.86856429 | CS |
| 4 | -0.12 | -12.2448979592 | 0.98 | 1.13 | 0.8224 | 196307 | 0.98886557 | CS |
| 12 | -0.24 | -21.8181818182 | 1.1 | 1.1373 | 0.8224 | 145610 | 0.98493215 | CS |
| 26 | -0.58 | -40.2777777778 | 1.44 | 1.7 | 0.8 | 275013 | 1.18984372 | CS |
| 52 | -1.61 | -65.1821862348 | 2.47 | 3.16 | 0.8 | 223753 | 1.60190482 | CS |
| 156 | -4.93 | -85.1468048359 | 5.79 | 9.7662 | 0.8 | 231820 | 3.38007161 | CS |
| 260 | -4.93 | -85.1468048359 | 5.79 | 9.7662 | 0.8 | 231820 | 3.38007161 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
